The study, published in Frontiers in Digital Health on 21 October 2026, assessed dedicated digitalization guidance from the American College of Rheumatology, the Asia Pacific League of Associations for Rheumatology and the European Alliance of Associations for Rheumatology. The sample comprised two ACR documents from 2023 and 2024, two EULAR documents from 2019 and 2022, and one APLAR telemedicine document from 2022. It was an interpretive document analysis rather than a systematic review or an evaluation of clinical outcomes.

Researchers searched PubMed and Google for English-language society publications from January 2019 through September 2025. Their terms combined the names of the three organizations with digitalization concepts including artificial intelligence, telemedicine, mobile health, rheumatology, guidelines, recommendations, points to consider and position statements. After screening 202 titles and abstracts and removing duplicates, the researchers selected five official guidance documents. They described this as the full set of dedicated digital guidance issued by those societies during the search period.

Two coders then applied a deductive framework built around three questions: whether ethical terms appeared, whether recommendations invoked or implicitly aligned with a normative theory, and whether trade-offs between competing values were acknowledged. The ethical vocabulary included autonomy, justice, beneficence, non-maleficence, informed consent, equity, data protection and privacy. The theoretical categories were principlism, utilitarianism, deontology or Kantianism, and virtue ethics. A fourth check considered tensions such as privacy versus innovation and efficiency versus equity.

All five documents mentioned data protection, privacy, patient-centeredness and access, but these terms were generally used as labels rather than developed into explicit arguments. The EULAR mobile health guidance, for example, lists user privacy and safety as criteria without defining how they should be handled when an application involves third-party services. The ACR artificial intelligence statement refers to bias and confidentiality, but the analysis found no detailed definition of those concepts or sustained discussion of their ethical implications.

The documents also did not explicitly cite any of the normative frameworks used in the analysis. Their recurring emphasis on system-level efficiency, population health benefits and technological progress resembled a utilitarian orientation in the researchers’ interpretation, but this pattern was not presented as an explicit ethical commitment. Nor was it balanced against deontological concerns such as individual rights, dignity and autonomy, or against the character and practical wisdom emphasized by virtue ethics. The authors described this as an interpretive hypothesis, not a demonstrated intention of the guideline developers.

Several difficult questions remained outside the documents. The ACR telemedicine statement acknowledged regional disparities, according to the analysis, without framing them as a justice problem requiring decisions about the equitable distribution of resources. APLAR recommendations referred to structural hurdles in the Asia-Pacific region but did not examine whether telemedicine could worsen inequalities for already marginalized patients. The study’s central distinction was between mentioning an ethical concept and showing how competing principles should be weighed when recommendations affect real people.

The authors cautioned that their result applies to the five selected publications and does not establish that ethical reasoning was absent from the committees’ internal deliberations. Practical pressures, an emphasis on implementation, editorial constraints and limited space could all have shaped the final texts. The analysis could identify only what was publicly documented, and it did not include interviews with developers. Its sample was also small, limited to English-language documents from three organizations, and focused on guidance specifically devoted to digitalization rather than broader ethics statements that touched on digital care only in passing.

Based on their findings, the researchers proposed minimum ethics components for future rheumatology guidance. They called for a dedicated section that identifies value tensions, explains how trade-offs were resolved and names the normative frameworks behind those judgments. They also recommended assessing effects on groups at risk of exclusion, including older, low-income, digitally excluded and non-native-speaking patients, with specific mitigation strategies. Guideline teams, they argued, should routinely include ethicists, patient advocates and social scientists alongside clinicians and technical experts, rather than treating them as occasional advisers.

The study is not a rejection of digital rheumatology. Its authors instead argue that tools such as telemedicine and algorithmic decision support can make preexisting value judgments more consequential by extending and scaling them. An AI system that improves population-level treatment allocation, for example, could also rely on opaque processes that weaken individual informed consent; expanding telemedicine may broaden access while excluding patients with limited digital literacy. By naming these conflicts, future guidelines could give clinicians and policymakers a clearer basis for deciding when the pursuit of aggregate benefit should be constrained by rights, dignity or equity. Whether current guidance becomes more ethically explicit remains an open question requiring broader and longitudinal research.

Subject of Research: Qualitative assessment of ethical reasoning in international rheumatology digitalization guidance

Article Title: From implicit assumptions to explicit ethics: assessment of normative frameworks in digitalization recommendations in rheumatology

Article References: Drexler, J., Richter, J. G., Buchkremer, R., Chehab, G., Killersreiter, B., & Thielscher, C. (2026). From implicit assumptions to explicit ethics: assessment of normative frameworks in digitalization recommendations in rheumatology. Frontiers in Digital Health, 8, Article 1928292. https://doi.org/10.3389/fdgth.2026.1928292

Image Credits: AI Generated

DOI: 10.3389/fdgth.2026.1928292

Keywords: digital health, rheumatology, telemedicine, artificial intelligence, clinical guidelines, medical ethics, health equity, normative frameworks, patient autonomy, data privacy, implicit, assumptions

Most neuro-oncology studies described technical performance, feasibility, retrospective analyses or planned work rather than demonstrated improvements in patient outcomes. Patient-reported outcomes, or PROs, are information reported directly by patients about symptoms, functioning and quality of life, without interpretation by a clinician. The review identifies pain, communication difficulty, perceived cognition, seizures, symptomatic adverse events, physical functioning and role functioning as priority constructs for high-grade glioma trials and clinical care.

Clinician-rated measures, including the Karnofsky Performance Status, Neurologic Function Score and Common Terminology Criteria for Adverse Events, remain central in neuro-oncology, while the Mini-Mental State Examination and Montreal Cognitive Assessment provide performance-based cognitive screening. These measures complement rather than replace PROs. Studies cited in the review found that clinicians can underestimate symptom frequency and severity, whereas cognitive impairment, aphasia and reduced insight can compromise self-reporting.

Caregiver proxies can provide information, but their interpretation introduces additional complexity. The quality of PRO data therefore constrains what AI systems can learn. Missing responses, selection bias, inconsistent assessment timing and disagreement between clinicians and patients can distort symptom trajectories, estimated treatment effects and model predictions.

Questionnaire completion commonly declines with respondent burden, clinical deterioration and logistical barriers. In a phase III trial of prophylactic cranial irradiation in extensive-stage small cell lung cancer, fewer than half the expected quality-of-life forms were returned at 12 months. Attrition is especially consequential because patients whose condition is worsening are more likely to stop responding, potentially reducing statistical power and biasing results.

The review notes that standardized schedules, electronic collection, reminders, staff education, compliance monitoring and appropriate methods for handling missing data may improve data quality, while each must accommodate differences in neurological status, communication and access. Evidence that frequent symptom monitoring can improve outcomes is strongest outside neuro-oncology. In a single-institution randomized trial involving 766 patients receiving chemotherapy for metastatic cancers, electronic PRO monitoring with automated nurse alerts reduced emergency-department visits, prolonged time on chemotherapy and improved one-year survival.

The PRO-TECT cluster randomized trial, conducted across 52 practices with 1,191 patients, reported that weekly electronic PRO surveys improved physical function, symptom control and health-related quality of life at three months in diverse community oncology settings. Brain-tumor evidence has largely remained at the feasibility stage. A glioblastoma smartphone-app pilot showed that longitudinal health-outcome tracking could include caregiver-proxy entries, while a separate study involving 43 patients with glioblastoma found that electronic PROMIS and EORTC assessments could be completed in a clinical setting.

These studies demonstrate feasibility rather than the clinical benefits reported in general oncology. Classical machine learning offers a way to analyze large and heterogeneous longitudinal PRO datasets by learning patterns from data rather than following fixed rules. Early work predicting health-related quality of life after low-grade brain-tumor resection used support vector machines and random forests; the classifiers achieved areas under the curve above 0.90 for most symptom outcomes using routine perioperative inputs.

A systematic review of machine-learning approaches to cancer symptom prediction found that temporal and longitudinal modeling were underrepresented and that neuro-oncology was absent. Natural language processing can extract structured information from free-text clinical notes, another large and largely untapped part of the medical record, but oncology-specific applications in neuro-oncology remain limited. Many such systems also require extensive manual rule development and domain-specific expertise, which can restrict adaptability across settings.

Large language models may extend the range of data that can be processed. In an analysis of 51,541 neuro-oncology clinical notes from an electronic health record, GPT-4o extracted nine symptom domains with mean sensitivity and specificity of 0.97. It identified an average of 3.92 symptoms per note, and reported symptom prevalence was substantially higher than in comparable clinical trials.

Patients receiving immune checkpoint inhibitors had the highest symptom burden, illustrating how automated extraction can provide treatment-stratified observations that complement prospective PRO instruments. The analysis did not establish that extracted symptoms can prospectively detect deterioration in primary brain-tumor patients or serve as substitutes for patient reports. That distinction is fundamental: a PRO originates directly from the patient, whereas an LLM-derived interpretation is an AI-derived measure and should be labeled and evaluated separately.

Broader assessments of patient-reported outcome models indicate weaknesses in validation and implementation. A 2024 systematic review of 52 oncology studies found that fewer than 8% of models had been externally validated and fewer than 6% shared reproducible code, despite a roughly twentyfold increase in machine-learning publications using PRO data between 2011 and 2021. A separate 2025 scoping review of 94 studies using PROM data to predict outcomes across clinical fields identified only 10 external validations and three studies that had reached implementation.

It also found inconsistent handling of missing data and limited patient or clinician involvement in model development. Because the reviews covered different scopes, they do not demonstrate a direct time trend. They do show that analytical performance has often been assessed without replication in independent settings.

Neuro-oncology faces additional constraints from disease heterogeneity, modest sample sizes and symptoms that patients may be unable to report, including seizures and neglect. Caregiver reports, wearable data and clinical narratives can supply complementary information. Integrating predictive systems into care presents separate challenges from developing them.

In a review of cancer symptom-management clinical decision-support systems, only 25.5% were integrated into electronic health records and 18.2% incorporated AI, with most relying on rules rather than predictive models. The review cites evidence favoring standardized terminology, high-yield alerts and a defined response whenever an alert is issued, because frequent low-specificity warnings can produce alert fatigue. Decisions based on unreliable data, or decisions that could cause harm if made incorrectly, may require clinician verification.

A modular autonomous workflow using five LLM agents to identify cognitive concerns in unstructured notes performed comparably to, but did not outperform, an expert-refined workflow on an independent validation set. Its inspectable structure made prompt refinement easier to review. In neuro-oncology, a glioblastoma remote-monitoring study registered in 2023 pairs Apple Watch biometric data with patient- or caregiver-entered symptoms, while a French glioma study registered in 2026 will evaluate a platform for neurologic symptoms, treatment tolerance and quality of life.

These protocols describe planned research and do not establish efficacy. Ethical requirements are particularly consequential for patients whose cognition or decision-making capacity may change over time. Informed consent and clear communication are needed about when AI is used, what information it processes, how its output could affect care and what alternatives exist.

A clinician should be able to inspect the original patient or proxy report, identify its source and review clinically consequential interpretations in context. If a large language model infers a symptom from a conversation, that output must not be presented as a patient-reported outcome. Privacy and security obligations also vary by jurisdiction.

In the United States, a provision of the 21st Century Cures Act can exclude certain clinician-facing decision-support functions from the definition of an FDA-regulated medical device when specified criteria are met, including independent clinician review of the basis for a recommendation; this is not a blanket exemption for AI or electronic-health-record tools. In the European Union, the General Data Protection Regulation governs personal and health-data processing, while the EU AI Act applies a risk-based framework to qualifying medical devices. Potential bias can arise from unrepresentative study populations, nonrepresentative clinical language, proxy variables, aggregation and selective feature use.

Clinical trial populations can underrepresent women and non-White patients, and symptom documentation may also differ across racial, ethnic, gender and socioeconomic groups. AI-generated summaries can intensify this problem when they present a narrow or skewed dataset as representative of a whole population. The review highlights equity-centered frameworks that require risk-benefit assessment, formal oversight and mechanisms for redress, alongside proposals to add explicability to established bioethical principles.

Its overall assessment is that AI and PRO systems could make neuro-oncology more patient-centered and data-driven, but current evidence is constrained by small studies, missing symptom data, inconsistent measurement and weak external validation. Progress depends on multicenter collaboration, standardized PRO frameworks, interoperable data systems, reproducible validation and broader inputs such as caregiver reports and wearables. Translation into care will require interpretable, electronic-health-record-integrated tools that provide actionable information while preserving patient consent, privacy, autonomy, equity and clinician oversight.

Subject of Research: Artificial intelligence for symptom assessment and patient-reported outcomes in neuro-oncology

Article Title: Artificial intelligence for symptom assessment and patient-reported outcomes in neuro-oncology

Article References: Yogendran, L. V., Avery, C., Crooms, R. C., Ozair, A., Siegel, C., Guterman, I., Rhee, J. Y., Binder, J., Minor, M., Alder, L., Davis, J., & Sharma, A. (2026). Artificial intelligence for symptom assessment and patient-reported outcomes in neuro-oncology. Journal of Neuro-Oncology, 180(2), Article 26. https://doi.org/10.1007/s11060-026-05832-9

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05832-9

Keywords: artificial intelligence, neuro-oncology, brain tumors, patient-reported outcomes, symptom monitoring, machine learning, large language models, clinical decision support, medical ethics, data bias, Artificial, intelligence

The authors identify code-status discussions as a recurring example of the problem. Clinical notes may record that a patient wishes to receive cardiopulmonary resuscitation after cardiac arrest, sometimes alongside qualifications about advanced comorbidities, clinical frailty, or the limited likelihood that CPR will benefit the patient. The authors argue that clinicians often respond by presenting available interventions and positioning themselves as neutral parties. They contend that this practice can shift the moral and emotional burden of life-and-death decisions to patients, families, or substitute decision-makers without distinguishing between a patient’s authority to refuse treatment and an unrestricted claim to receive any requested intervention.

The critique is grounded in the principlist framework associated with Beauchamp and Childress, which allows competing moral principles to override respect for autonomy and rejects any fixed hierarchy among principles. Winberg and Slessarev describe how an autonomy-focused approach can become dominant in clinical practice: clinicians offer options, outline risks and benefits, obtain informed consent, and regard their ethical obligations as fulfilled. They call the resulting model consumeristic because patients or substitute decision-makers may bear responsibility for choices made during periods of vulnerability. According to the essay, this shift can weaken shared responsibility and the patient-physician relationship, although the authors do not present measured outcomes from the model.

The authors distinguish the autonomy trap from every decision to provide CPR that clinicians judge unlikely to benefit a patient. CPR may be unable to restore circulation, or it may restore circulation without producing an outcome clinicians consider worthwhile. The latter includes judgments about survival, disability, suffering, and the value of additional time, which are not purely physiological. Patients and families may value brief survival, the assurance that clinicians did not give up, or freedom from feeling responsible for a relative’s death. These considerations may reflect cultural, religious, or social understandings of a good death. The authors state that failure to recognize such meanings can contribute to distrust and inequity, but their essay does not quantify those effects.

They also caution that providing CPR in carefully selected cases after considering broader benefits may itself be an exercise of professional judgment rather than an abdication of responsibility, provided clinicians consider potential suffering. The problematic pattern, in their view, is supplying CPR solely because it was requested without evaluating, communicating about, or accepting responsibility for its medical and ethical appropriateness. This distinction means the essay does not characterize all patient requests for resuscitation as irrational or inappropriate, nor does it support unilateral decisions without contextual evaluation.

The authors propose three origins for the autonomy trap. First, they associate the growth of bioethics with neoliberal economic structures emphasizing market primacy, individualism, and preference maximization, noting that respect for autonomy aligns readily with an understanding of patients as consumers. Second, they identify defensive medicine, defined as practice driven by concern about litigation rather than patient benefit, as a factor that may encourage clinicians to defer to requested interventions to avoid legal, reputational, and institutional pressures. Third, they describe a collapse of administrative and clinical contexts: the former establishes what the biomedical community regards as legitimate medical care, while shared decision-making allows a patient to select among established options that fit their values.

The consequences they anticipate include burdens on patients making decisions during acute stress, pain, and uncertainty; guilt and delayed remorse after informed decisions; and the offer of interventions that cannot achieve their intended goal, which they describe as false choices. Clinicians who provide care they believe is misaligned with a patient’s best interest or approaches harm may experience moral distress and disengagement from outcomes. These are arguments advanced by the viewpoint, not findings from a cohort, simulation, survey, or other outcome study, and the article provides no estimates of their frequency or magnitude.

To avoid the trap while preserving the rejection of paternalism, the authors say physicians should first determine which interventions are medically appropriate through thorough clinical assessment, supplemented where applicable by validated prognostic and risk-stratification tools. Recommendations should integrate prior wishes, baseline functional status, comorbidities, current illness severity and trajectory, treatment risks and benefits, and the patient’s values and acceptable outcomes. Because the efficacy of advance care planning is mixed, they argue that clinicians should help construct values-based care plans in real time amid clinical uncertainty. They frame evidence-informed assessment combined with patient values as shared responsibility rather than a unilateral command.

Trust is central to this model, according to the essay. Clinicians are encouraged to demonstrate competence, communicate clearly and honestly, listen with empathy, explore the patient’s experience, and provide understandable information. The authors also recommend ethics education that deepens understanding of principlism while familiarizing clinicians with care ethics and virtue ethics. They describe microethics as a practical lens for self-reflection, perspective-taking, cultural humility, and attention to how language, framing, and behavior shape trust and redistribute decision-making responsibility. Their final claim is that autonomy remains indispensable to medicine, yet respect for autonomy and informed consent alone cannot carry the full ethical responsibility of care.

Subject of Research: A bioethics viewpoint on balancing patient autonomy with clinical judgment and shared responsibility in care decisions.

Article Title: The Autonomy Trap: When Respect for Choice Becomes Withdrawal of Professional Responsibility

Article References: Winberg, C., & Slessarev, M. (2026). The Autonomy Trap: When Respect for Choice Becomes Withdrawal of Professional Responsibility. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10866-w

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10866-w

Keywords: medical ethics, patient autonomy, shared decision-making, clinical judgment, cardiopulmonary resuscitation, code status, defensive medicine, advance care planning, professional responsibility, Autonomy, Trap, Respect

The clinical course was technically straightforward. The woman, who had obesity and obstructive sleep apnea, arrived with dyspnea and tense ascites. Her MELD-Na score of 27 and Child-Pugh C status marked her as having decompensated cirrhosis with a prognosis measured in months, and she was not a liver transplant candidate. Her hospital stay was complicated by hepatic encephalopathy, which resolved with lactulose and rifaximin, followed by hypercapnic respiratory failure with a pH of 7.1 and pCO2 of 70 mmHg. She improved on BiPAP but could not tolerate the mask. A goals-of-care conference documented DNR/DNI status and comfort measures only. Over the following week, her creatinine rose from 1.6 to 4.4 mg/dL, consistent with acute kidney injury on cirrhosis, driven by massive ascites and persistent hypotension. She remained relatively asymptomatic. The medicine was appropriate. The system around it was not.

The barrier emerged at the moment of discharge. The woman was widowed; her only family were elderly siblings. Her sister was housebound due to her own medical conditions, and her brother, who held her power of attorney, was caring for an ill partner a thousand miles away. Around-the-clock home care was impossible. She required nursing facility placement with hospice—but the Medicare hospice benefit, established in 1982, does not cover room and board in a nursing facility. She had no savings. A Medicaid application was submitted, but approval remained pending. One nursing home demanded two months of room and board payment upfront: $18,000. Some facilities nationally do accept Medicaid-pending patients, absorbing short-term financial risk with the expectation of retroactive reimbursement. The facilities in her area did not. After four days without urine output, a skilled nursing facility finally accepted her into a subacute bed under Medicare billing. She was transferred and died shortly thereafter. The coverage gap was bridged not by policy but by clinical deterioration severe enough to qualify for an alternative billing pathway.

The authors are careful about the policy conditions surrounding the case. It occurred in a Medicaid expansion state, at a safety-net hospital, in an urban center with multiple hospice agencies. On paper, the woman qualified for both Medicare and Medicaid. Federal law allows 45 days for Medicaid eligibility determination, though average processing time frequently approaches 90 days. Her prognosis was days to weeks. The gap between eligibility and approval exceeded her survival. The medical team could not execute her wishes. The hospital could not discharge her while she was present and aware. The barrier was not clinical judgment or individual failure, the authors write. It was structural—a policy gap between program eligibility and program access.

The ethical analysis cuts across all four foundational principles of medical ethics. Autonomy was compromised: she had decisional capacity, documented goals of care, and family agreement, but her choice could not be delivered. Beneficence was compromised in a form the authors identify as moral distress—knowing the right course and being prevented from taking it, a condition shared by the medical team, the hospice agencies, and the hospital alike. Non-maleficence was compromised environmentally: the harm of overhead pages and beeping monitors was caused not by anyone’s action but by the absence of an alternative. And justice was compromised in the starkest terms. The same patient enrolled in VA care would have received a different death, because the VA hospice benefit covers room and board in VA Community Living Centers and contracted community nursing homes with no upfront payment required. The death experience differed solely based on which system one enrolled in and who one is.

The case is not isolated, and the literature the authors review documents a pattern of structural barriers across populations and disease categories. A 2023 study of Medicaid-only and dual-eligible decedents found that Hispanic and non-Hispanic Black individuals had the lowest odds of receiving hospice care compared to non-Hispanic White individuals, with Hispanic decedents also having the highest odds of short hospice stays. Research shows hospice patients with lower incomes are significantly more likely to die in hospitals rather than at home, with the association strongest among patients requiring facility-based care. Hospice is particularly underutilized in decompensated cirrhosis: the AASLD Practice Guidance on Palliative Care reports that only 11% of these patients receive specialty palliative care or hospice referrals, often very late in the disease course, even though patients with MELD-Na above 21 or Child-Pugh score of 12 or higher have an estimated survival of six months or less and are prognostically appropriate. Even under universal healthcare, greater social deprivation independently predicted lower end-of-life care quality ratings among patients with liver disease—suggesting structural disadvantage shapes outcomes beyond insurance coverage alone.

What the literature does not document, the authors note, is the mechanism—the specific procedural sequence by which a patient who qualifies for both Medicare and Medicaid is nonetheless unable to access chosen end-of-life care in a chosen environment. Published case reports examining the Medicare-Medicaid coverage gap as a barrier to hospice access are absent. The temporal mismatch between Medicaid processing timelines and terminal prognosis has not been previously described in clinical case literature. This case fills that gap, and in doing so exposes a deeper demographic mismatch. The Medicare hospice benefit was built on the assumption that dying patients will be cared for at home by family. In 1982, when 11% of the US population was 65 or older and life expectancy at age 65 was 16.8 years, that assumption reflected demographic reality. It does not reflect our times.

The numbers tell the story of a society that dismantled its communal safety-net without rebuilding the policy infrastructure to replace it. Today 17% of the US population is 65 or older, and 28% of adults 65 and older—16.2 million people—live alone; among women 75 and older, 43% live alone. Among those who do have caregivers, 17% are themselves 65 or older, and 53% of those caregivers have two or more chronic diseases. Roughly one in three older adults lives at or below 200% of the federal poverty level, and one in five adults over 50 has no retirement savings. Among Medicare beneficiaries, 25%—approximately 15 million people—have incomes below the federal poverty level. While 71% of Americans prefer to die at home, only 30% achieve this goal. The benefit fails in both directions: even patients who can be discharged home receive inadequate custodial care support, with less than two hours of aide services per week under routine hospice and a per diem reimbursement that cannot cover basic caregiving needs, as documented by Knight and colleagues. For patients like this woman—widowed, childless, with elderly siblings caring for their own ill partners—the question of family willingness is irrelevant. Family capacity does not exist.

The authors offer practical and policy implications. For clinicians, the case highlights the importance of anticipatory Medicaid application for patients with terminal conditions: primary care physicians and gastroenterologists seeing patients with Child-Pugh C cirrhosis who are not transplant candidates should consider initiating Medicaid applications early, before decompensation and hospitalization, because the trajectory is known and processing times approaching 90 days require anticipation. For policy, expedited Medicaid determination for patients with terminal diagnoses would close the temporal gap this case documents—a procedural fix within existing federal programs, not a structural overhaul. Expedited pathways already exist in some states for medical emergencies. Social Model Hospice Homes, community-supported residential facilities providing around-the-clock care outside Medicare and Medicaid billing structures, represent an emerging alternative that sidesteps the coverage gap, though their reach is limited to the communities that sustain them—a local solution to a national problem.

The deeper fix, the authors conclude, requires confronting what the health system owes its members. Medicare policy should reflect today’s demographics, not the family structure of 1982. The counterargument—that Medicare is health insurance, not housing assistance, and room and board are living expenses outside the scope of any health system obligation—minimizes the bigger issue. The question is not whether Medicare should pay rent. The question is whether a patient has the right to die in a peaceful environment, and whether the health system has an obligation to make that possible. Dignity at end of life is not a luxury. It is the last expression of autonomy a person has. Working Americans who contribute to Medicare throughout their careers are owed that. This case, the authors write, demonstrates the scar—and the suffering was not the patient’s alone.

Subject of Research: End-of-life care policy and the Medicare-Medicaid coverage gap

Article Title: The Last Expression of Autonomy: A Case of Ethical Failure in End-of-Life Care

Article References: Lee, T. C., Ghosh, S., & Braund, V. L. (2026). The Last Expression of Autonomy: A Case of Ethical Failure in End-of-Life Care. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10774-z

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10774-z

Keywords: end-of-life care, hospice access, Medicare hospice benefit, Medicaid coverage gap, medical ethics, palliative care, cirrhosis, health policy, moral distress, autonomy, Last, Expression

The research team, led by Yanan Xu and Li Zhang of Bengbu Medical University together with colleagues from Nanjing Drum Tower Hospital and the First Affiliated Hospital of Nanjing Medical University, conducted semi-structured interviews with eighteen nurses recruited through purposive sampling — a technique that deliberately selects participants with direct, relevant experience rather than drawing them at random. The interviews were systematically coded, with researchers organizing recurring ideas into themes, a standard qualitative method that transforms hours of conversation into a structured map of professional opinion. The study was reported according to the Consolidated Criteria for Reporting Qualitative Research, or COREQ, a 32-item checklist designed to make qualitative studies transparent and reproducible. Ethical approval came from the Ethics Committee of Gulou Hospital, Nanjing University School of Medicine, and every participant gave informed consent before taking part.

Four main themes emerged from the analysis, and together they read like a blueprint for how AI might — and might not — belong at the bedside of the dying. The first theme was recognition of AI’s potential value. The second concerned the real-world challenges that stand in the way of integration. The third captured ethical worries about privacy, fairness, and responsibility. The fourth described ethical tensions embedded in nursing practice itself. That structure matters because it separates practical barriers from moral ones, a distinction that engineers and hospital administrators often blur when they pitch new clinical tools.

On the practical side, the nurses saw AI as potentially useful in three concrete domains: workload support, symptom assessment, and communication. Anyone who has spent time in palliative care knows why these three came first. Nurses in this field juggle complex medication regimens, frequent reassessments of pain and breathlessness, and emotionally exhausting conversations with patients and families — often simultaneously. An algorithm that could automate documentation, flag subtle changes in a patient’s symptom trajectory, or help draft clear explanations for anxious relatives would free up the scarcest resource in end-of-life care: the nurse’s undivided attention. Symptom assessment is a particularly promising target, because palliative symptoms such as pain, dyspnea, and delirium fluctuate in ways that are easy to miss between rounds, and machine learning models excel at detecting patterns in longitudinal data that humans overlook.

Yet the nurses were equally clear-eyed about the obstacles. They questioned whether current AI systems could adapt to the realities of palliative care, where patients’ conditions change rapidly and where the goals of care often shift from cure to comfort. They also flagged a skills gap: AI literacy among nursing staff is uneven, and a tool that requires technical fluency the workforce does not possess risks becoming shelfware or, worse, a source of error. This concern echoes a broader finding in health informatics — that the success of clinical AI depends less on the sophistication of the model than on the fit between the model and the clinical workflow, and on the training of the people expected to use it.

The ethical concerns were the study’s most striking contribution, and they cluster around three concepts: privacy, fairness, and responsibility. Privacy is self-evident in a setting where patients share their fears, family conflicts, and end-of-life wishes with their caregivers; the nurses worried about where that information goes once it feeds a machine-learning system, who can access it, and whether consent obtained in a hospital corridor can truly cover algorithmic processing of the most personal data a person will ever disclose. Fairness concerns arise because AI models trained on data from certain populations can perform poorly for others — older patients, people with rare conditions, or those whose symptom expression differs from the training data — potentially compounding inequities at the very moment of life when no one can afford to be underserved.

Responsibility proved the thorniest issue of all. If an AI system misjudges a symptom or recommends an inappropriate intervention, who answers for it — the nurse who followed the recommendation, the clinician who deployed the system, the vendor who built it, or the hospital that purchased it? The nurses raised questions about accountability and autonomy that map directly onto an unresolved debate in AI governance: the problem of meaningful human control. In palliative care, where decisions carry irreversible weight, the nurses’ insistence that a human must remain in the loop is not technophobia; it is a demand that responsibility remain assignable to a person, not dissolved into an opaque statistical process.

Beneath these practical and governance concerns lies a deeper tension the nurses described in their own practice: the preservation of humanistic care. Palliative nursing is built on presence, touch, listening, and the willingness to sit with suffering that cannot be fixed. The participants worried that an efficiency-driven technology, however well-intentioned, could erode precisely the qualities that make end-of-life care humane — that a screen between nurse and patient might substitute transaction for relationship. This is the study’s viral insight, the one that should stop every AI developer mid-pitch: in this setting, the highest-value feature of any technology is that it gives nurses more time for the human work, not that it performs the human work itself.

The study’s findings arrive at a moment when healthcare systems worldwide are racing to integrate AI into clinical practice, often with governance frameworks that lag behind deployment. By documenting the views of nurses — the largest workforce in healthcare and the group in closest continuous contact with patients — the research provides evidence for future AI design, training, and governance in palliative care. The authors suggest their results can inform how developers build tools that respect the realities of end-of-life settings, how educators prepare nursing staff to use them competently, and how institutions write policies that assign responsibility clearly and protect patient privacy and fairness.

The study has limits worth noting. Eighteen nurses in a single country cannot speak for every palliative care setting, and qualitative descriptive studies capture perceptions rather than measured outcomes — the nurses’ views on AI’s potential are hypotheses to be tested, not evidence of what AI can actually achieve at the bedside. Still, as the first systematic exploration of this question in end-of-life nursing, the research fills a conspicuous gap. The message from the people who hold dying patients’ hands is ultimately a challenge to the AI industry: bring your algorithms into palliative care if you must, but design them to serve human connection, prove they are fair and private, and never ask them to replace the human presence that patients at the end of life need most.

Subject of Research: Palliative care nurses' views on AI and ethical dilemmas

Article Title: Exploring palliative care nurses’ views on the potential of AI and ethical dilemmas: a qualitative study

Article References: Xu, Y., Jing, J., Yan, Z., Ji, X., Zhou, Y., & Zhang, L. (2026). Exploring palliative care nurses’ views on the potential of AI and ethical dilemmas: a qualitative study. BMC Nursing. https://doi.org/10.1186/s12912-026-05318-z

Image Credits: AI Generated

DOI: 10.1186/s12912-026-05318-z

Keywords: artificial intelligence, palliative care, nursing, medical ethics, healthcare technology, qualitative research, Exploring, palliative, care, nurses, views, potential

The perspective, written by Kellie Owens, Maggie Ramatowski, and Saul B. Blecker of New York University Grossman School of Medicine, draws on social science research and the authors’ own experiences deploying AI models in real healthcare settings. Their central claim is technically precise and socially explosive at the same time: implementation itself is a major driver of bias in healthcare AI. The ways AI systems are adopted, interpreted, and applied in practice—shaped by institutional norms, professional hierarchies, and patient characteristics—can reproduce or even amplify inequities that no dataset diversification could ever prevent.

The technical foundation of the argument rests on a distinction that fairness engineering has largely ignored. Most current approaches to algorithmic fairness draw on principles of distributive justice, asking whether a model allocates recommendations or resources equitably across socially salient groups such as race, gender, or age. A model might show similar sensitivity or positive predictive value across demographic groups—hallmark mathematical signals of fairness—and still introduce bias at the point of use. The reason is that these metrics presume model outputs directly drive decisions, when in reality clinicians serve as crucial intermediaries. Clinicians choose whether to consult a model at all, and each decision point introduces variation, and with variation comes the potential for bias.

Social scientists have long documented that algorithmic outputs are not inert facts but tools shaped by interpretation and context. Prior research on how clinicians act on algorithmic input shows that they may use or ignore recommendations based on their own judgments of the model’s value, and that healthcare workers and patients hold different expectations that shape how data is understood. AI outputs become embedded in complex feedback loops, altering individual decisions, broader workflows, and professional norms. The introduction of AI into clinical care is deeply social, woven into institutional routines, power dynamics, and historically rooted patterns of discrimination. Understanding these dynamics, the authors insist, requires looking beyond the algorithm itself.

Although the authors are unaware of studies directly examining bias in the implementation of AI-based algorithms in healthcare, emerging evidence from clinical decision support systems offers troubling clues. Studies indicate that the effectiveness of decision support tools can differ across gender and age, and some reports suggest providers may incorporate recommendations differently depending on patient characteristics. These patterns of uneven uptake may reflect familiar dynamics—workflow constraints, trust levels, or cognitive biases such as automation bias, in which clinicians defer to system outputs without adequate scrutiny. Clinicians often do not even know whether a decision support tool is AI-based.

Yet AI may introduce distinct challenges of its own. Because AI systems are often perceived as more objective or personalized than traditional decision support, they may heighten automation bias, making clinicians more likely to accept outputs at face value. Conversely, limited AI literacy or lack of transparency can make it difficult for clinicians to appropriately evaluate model outputs, producing overreliance in some cases and unwarranted skepticism in others. In the authors’ own research and experience, clinicians may use AI models differently depending on which patient is in front of them, mirroring existing power dynamics and social hierarchies. Clinicians may be more likely to accept AI recommendations at face value for marginalized patients, while subjecting outputs to greater scrutiny or repeated testing for more socially advantaged patients. Fairness, in other words, is entangled with dynamics of trust, authority, and power—not reducible to model accuracy alone.

This finding strikes at the heart of the most widely proposed safeguard in AI governance: the human-in-the-loop. The assumption behind this strategy is that clinicians, by exercising judgment, will act as a fail-safe against algorithmic error or bias. The authors suggest the opposite. Clinicians themselves are a major site where inequities emerge, and placing primary responsibility for fairness on individual clinicians risks reinforcing rather than mitigating structural inequities. Humans, they write, are often the very conduit through which inequities enter the system. Institutions that assume human oversight guarantees fairness are making a dangerous assumption—one that recent literature has begun to question, with some proposals favoring supervisory oversight over more autonomous systems instead of active clinician-AI collaboration.

To move from descriptive concern to testable science, the authors lay out a concrete research agenda. One approach is to examine whether and how clinicians differentially use, ignore, or override AI recommendations based on patient characteristics such as race, gender, or socioeconomic status, using audit log data linked to clinical and demographic information. A second line of inquiry should focus on conditions of use: whether time pressure, workload, or alert fatigue increases reliance on AI, and whether these effects vary across patient groups. Qualitative and ethnographic approaches—observational studies of clinical workflows and in-depth interviews with clinicians and patients—can surface how AI outputs are made meaningful in context and how competing definitions of fairness are reconciled in practice. Finally, linking patterns of AI use to downstream clinical decisions and outcomes is essential to determine whether these dynamics translate into inequities in care.

On the governance side, the authors call for a shift from human-in-the-loop to system-in-the-loop oversight, placing responsibility across healthcare organizations, regulators, and technology vendors. That framework includes continuous monitoring for disparities in AI use and outcomes across patient populations, with dashboards that track differential exposure to AI recommendations, override rates, and downstream outcomes by relevant subgroups. Institutional policies should standardize when AI recommendations must be considered or documented—for example, requiring clinicians to provide brief justification when overriding certain recommendations, or generating periodic audit reports for review by governance committees. Workflows should account for clinician workload and decision fatigue, recognizing that alert fatigue or lack of time may systematically disadvantage some groups of patients more than others. Vendors, too, should bear greater responsibility for post-deployment monitoring, transparency, and collaboration with health systems, including providing tools for subgroup performance auditing and tracking clinician interaction patterns.

The authors are careful to note that differences in how AI tools are used across patient groups are not necessarily evidence of unfair implementation. A high override rate for a particular group could indicate either appropriate clinical correction of model outputs or inequitable disregard of recommendations—disentangling the two is precisely what systematic tracking is for. But the broader message is unambiguous. Fairness is not only designed into models; it is negotiated and enacted in practice. By acknowledging that clinicians are not neutral backstops but active participants whose judgments are socially patterned, healthcare systems can design governance strategies that take human behavior seriously. The future of equitable AI in medicine, this perspective argues, depends less on perfecting the algorithm and more on governing the messy, human system around it.

Subject of Research: Health equity and AI governance in clinical decision support

Article Title: Promoting Fairness in AI Implementation

Article References: Owens, K., Ramatowski, M., & Blecker, S. B. (2026). Promoting Fairness in AI Implementation. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10767-y

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10767-y

Keywords: artificial intelligence, healthcare AI, algorithmic bias, clinical decision support, health equity, human-in-the-loop, AI governance, medical ethics, Promoting, Fairness, Implementation, scientific research

The finding lands at a moment when health systems worldwide are grappling with unprecedented staff shortages and burnout. But the German data suggest that what is hollowing out the nursing workforce may not be simple exhaustion. It may be something darker and harder to measure: the accumulating damage done when professionals are forced, day after day, to act against their own moral convictions — or to watch the care they know patients deserve become impossible to deliver.

Moral injury entered the medical literature relatively recently. The concept originated in military psychology, where it described the lasting psychological burden suffered by service members who participated in, witnessed, or failed to prevent events that violated their deepest moral beliefs. Unlike post-traumatic stress disorder, which is rooted in fear, moral injury is rooted in conscience. It manifests as guilt, shame, spiritual anguish, and a corrosive sense of having been condemned — by others, by institutions, or by oneself. Only in recent years, accelerated by the strains of the coronavirus pandemic, have researchers begun applying the framework to health care workers, and nurses in acute inpatient care have emerged as a population at particular risk.

The new study distinguishes moral injury from a related but separate phenomenon: moral distress. First defined by philosopher Andrew Jameton in 1984, moral distress arises when a nurse knows the right thing to do but institutional constraints — understaffing, budget pressure, hierarchy — make it nearly impossible to do it. Moral distress is the acute friction of the moment. Moral injury, by contrast, is what may follow when that friction repeats without relief. The research team, led by Tobias Mai of University Hospital Goethe University Frankfurt, set out to measure both constructs in the same population for the first time in Germany, and to test whether the two are linked in the way an emerging ‘escalation model’ proposes: distress compounding, over time, into injury.

The methodology was deliberately rigorous. Participants completed the German Moral Distress Scale, the German Moral Injury Symptom Scale for Health Professionals, and the Perceived Organizational Support Scale, along with a questionnaire on the ethical and structural conditions of their institutions. Rather than relying on raw questionnaire totals, the researchers fitted partial credit Rasch models — a class of statistical models from item response theory that weight each question by its difficulty and convert responses into interval-level measures of the underlying trait. This approach, the authors argue, produces more robust estimates than classical scoring, because it acknowledges that some items probe more severe experiences than others and that the probability of a given answer depends on both the respondent’s true level of suffering and the sensitivity of the question.

The results were stark. The median moral injury score in the sample was 35 on a scale where the clinical screening threshold sits at 29, and the median moral distress intensity score was 30 out of a possible 48. Three sources of distress dominated: inadequate shift staffing, cited at high intensity by 55 percent of respondents; operational and financial pressure, cited by 39 percent; and insufficient competence among colleagues, also cited by 39 percent. More than half of the nurses reported encountering these morally corrosive situations at least once a week. And in a detail that underscores the systemic nature of the problem, 89 percent reported staff absences during their most recent shift.

The statistical relationship between the two constructs was unambiguous. Spearman correlation analysis revealed a strong positive association between moral distress and the guilt-and-shame dimension of moral injury (r = 0.57), with weaker but still significant links to the condemnation dimension (r = 0.39) and spiritual troubles (r = 0.22). In a univariate logistic regression, each one-unit increase on the Rasch-scaled moral distress measure was associated with 5.26-fold greater odds of screening positive for clinically relevant moral injury symptoms. A receiver operating characteristic analysis found that a moral distress score of 27 or higher on the raw scale identified moral injury cases with 71 percent sensitivity and 71 percent specificity — good, but far from perfect. Roughly 29 percent of nurses with moral injury symptoms were not flagged by their distress scores alone, evidence that the two constructs are empirically entangled yet conceptually distinct, and that measuring one cannot substitute for measuring the other.

Perhaps the most consequential findings concern what makes suffering worse — and what appears to protect against it. Perceived organizational support, measured on a seven-point scale, averaged just 3.37 in the sample, below the midpoint, and lower support was significantly associated with higher levels of both moral distress and moral injury across multiple dimensions. Conversely, nurses who reported satisfaction with how the treatment team considered their professional perspective during planned communication showed significantly lower scores on both measures. Having formal responsibility for staff was linked to lower guilt-and-shame and spiritual-troubles scores, a pattern the authors tentatively attribute to the greater decision-making autonomy that leadership roles confer. Years of professional experience, too, were associated with lower scores on the condemnation dimension of moral injury, suggesting that some form of moral hardening or accumulated coping capacity may develop over a career.

Not every intuitive intervention showed a protective effect, and the exceptions are instructive. Participation in interprofessional case discussions was actually associated with higher guilt-and-shame scores, and ethics consultations with higher spiritual-troubles scores. The researchers offer a candid interpretation: structured reflection on ethically fraught situations may initially sharpen nurses’ awareness of moral transgressions and intensify feelings of guilt before any therapeutic benefit materializes. Supportive structures were also strikingly underused — only about half of respondents had access to interprofessional case discussions or peer consultation, a quarter to supervision, and fewer than 12 percent to ethical guidelines at all.

The authors are careful about the limits of their design. The sample was recruited through professional societies and hospital networks rather than randomly, so more burdened nurses may have been more likely to respond, and the cross-sectional data cannot establish whether moral distress actually develops into moral injury over time — only that the two travel together. The regression models explained a modest share of the outcome variation, and no adjustment for multiple testing was applied, so the identified associations require confirmation. Still, the sheer scale of the sample, the randomization of questionnaire order to control for response bias, and the use of Rasch modeling lend the central findings considerable weight. The study is registered in the German Clinical Trials Register and was approved by the ethics board at University Medicine Greifswald.

What emerges is a picture of a workforce whose suffering is not a personal failing but an organizational product — and, the authors argue, an organizational responsibility. Where nurses felt valued, heard in team decisions, and supported by leadership, moral suffering was measurably lower. Where staffing collapsed and perspectives were ignored, it climbed. The researchers call for a shift away from framing the problem as insufficient individual resilience and toward shared institutional accountability: protected time and space for moral reflection, genuine inclusion of nursing perspectives in clinical communication, and leadership that treats ethical climate as infrastructure rather than ornament. With sickness-related absences among German care professionals rising steadily and staffing-related distress already exceeding levels reported in comparable Swiss and outpatient samples, the study’s warning is difficult to ignore. The moral wounds being documented are not incidental to the nursing shortage — by this evidence, they may be one of its driving forces.

Subject of Research: Moral distress and moral injury among nurses in German acute inpatient care

Article Title: Moral distress and moral injury among nurses in German acute inpatient care – a cross-sectional study

Article References: Mai, T., Seidlein, A.-H., Schilder, M., & Dahmer, I. (2026). Moral distress and moral injury among nurses in German acute inpatient care – a cross-sectional study. BMC Nursing, 25(1), Article 990. https://doi.org/10.1186/s12912-026-05526-7

Image Credits: AI Generated

DOI: 10.1186/s12912-026-05526-7

Keywords: moral injury, moral distress, nursing, acute care, organizational support, occupational mental health, Rasch analysis, healthcare workforce, medical ethics, staffing shortages, Germany, cross-sectional study

The study, published in BMC Nursing by Mihwa Kim of Pusan National University Hospital and Jungmi Yun of Pusan National University, surveyed 125 advanced beginner nurses working in the intensive care units of two tertiary hospitals in South Korea. Participants had between 13 and 36 months of total clinical experience, a range that places them squarely in the advanced beginner stage as defined by Jang’s adaptation of Benner’s well-known novice-to-expert model. In that framework, advanced beginners have moved beyond rule-following novices but still lack the deep situational judgment that characterizes competent and expert practitioners, making them a particularly important group to study in high-stakes settings.

Data were collected in March and April 2025 through a structured online self-report questionnaire. The researchers measured four distinct constructs: moral sensitivity, assessed with the Korean Moral Sensitivity Questionnaire; role conflict, the tension nurses feel when competing expectations pull them in different directions; the perceived ethical climate of the hospital, measured with the Hospital Ethical Climate Survey; and ethical decision-making, which was captured in two separate forms. Participants rated both what they judged would be ideally appropriate in an ethical situation and what they believed would realistically occur in practice, using the Judgement about Nursing Decision instrument.

The results revealed a striking gap between the ideal and the real. On a five-point scale, the nurses’ mean score for ideal ethical decision-making was 3.69, while their mean score for realistic ethical decision-making was just 3.15. The difference of 0.54 points was highly statistically significant, with a 95 percent confidence interval of 0.46 to 0.61, a t-value of 13.69, and a p-value below 0.001. The effect size, expressed as Cohen’s d of 1.23, is large by conventional standards. In practical terms, these nurses clearly recognized what the ethically appropriate response would be, yet they simultaneously expected that the response actually enacted on the ward would fall short of that standard.

Moral sensitivity itself scored 4.89 on a seven-point scale, indicating a moderately high level of awareness of ethical issues among the participants. Role conflict averaged 3.71 on a five-point scale, and perceived ethical climate averaged 3.74. These baseline figures set the stage for the study’s central analytical question: which of these factors, if any, would predict the two forms of ethical decision-making once the researchers accounted for nurses’ general characteristics such as experience and unit type?

To answer that question, the team ran multiple linear regression models that included all general characteristics together with the three study variables. For ideal ethical decision-making, moral sensitivity emerged as a significant positive predictor, with an unstandardized coefficient of 0.18, a 95 percent confidence interval of 0.02 to 0.34, a standardized beta of 0.20, and a p-value of 0.029. Total clinical experience, experience on the current unit, and working in an emergency ICU were also associated with ideal decision-making. The full model explained a modest 14.7 percent of the variance after adjustment.

Realistic ethical decision-making told a somewhat different story. Here, moral sensitivity was again a significant predictor, and a stronger one, with an unstandardized coefficient of 0.26, a confidence interval of 0.11 to 0.42, a standardized beta of 0.30, and a p-value of 0.001. But the perceived ethical climate also mattered, contributing an unstandardized coefficient of 0.20, a confidence interval of 0.07 to 0.33, a standardized beta of 0.28, and a p-value of 0.003. This model explained 20.7 percent of the variance after adjustment, still modest but noticeably better than the ideal-decision model. Role conflict, despite its theoretical importance, was not significantly associated with either form of decision-making in the final models.

The distinction between the two outcome types carries real weight for how the findings should be interpreted. Ideal ethical decision-making reflects what a nurse believes ought to happen, a judgment rooted largely in personal moral reasoning. Realistic ethical decision-making reflects what the nurse expects will actually happen, a judgment shaped by the surrounding organizational reality. The fact that perceived ethical climate predicted only the realistic form suggests that the ward environment, with its norms, hierarchies, and support structures, exerts its influence precisely at the point where moral intention is translated into expected action. Nurses who perceived their hospital’s ethical climate more favorably expected a smaller gap between the ideal and the real.

The authors are careful about the limits of their design. As a cross-sectional study using convenience sampling at two tertiary hospitals, the work captures a single point in time and a specific population, so causal direction cannot be established and the findings may not generalize to all ICU settings or to nurses at other career stages. The explanatory power of both regression models was modest, meaning that many other factors beyond moral sensitivity and ethical climate almost certainly shape how these nurses reason through ethical problems. The researchers themselves note that these factors warrant further consideration in the development and evaluation of support strategies, and they call for longitudinal and intervention studies to test whether the associations hold over time and whether targeted programs can strengthen them.

Even with those caveats, the study offers a concrete signal for hospital administrators and nursing educators. If moral sensitivity is associated with both what new ICU nurses believe should be done and what they expect will be done, then educational interventions that sharpen ethical awareness could pay dividends across the board. And if the perceived ethical climate is tied to the realistic side of the equation, then improving the moral texture of the workplace itself, through leadership, open discussion of ethical cases, and visible institutional support, may be the lever that closes the gap between what nurses know is right and what they expect to see happen at the bedside. For a workforce navigating its first years in one of medicine’s most ethically charged arenas, that gap may be the most important metric of all.

Subject of Research: Ethical decision-making among advanced beginner nurses in intensive care units

Article Title: Moral sensitivity, role conflict, ethical climate, and ethical decision-making among advanced beginner nurses in intensive care units: a cross-sectional study

Article References: Kim, M., & Yun, J. (2026). Moral sensitivity, role conflict, ethical climate, and ethical decision-making among advanced beginner nurses in intensive care units: a cross-sectional study. BMC Nursing. https://doi.org/10.1186/s12912-026-05519-6

Image Credits: AI Generated

DOI: 10.1186/s12912-026-05519-6

Keywords: nursing ethics, intensive care units, moral sensitivity, ethical climate, role conflict, ethical decision-making, advanced beginner nurses, Benner's model, cross-sectional study, South Korea, end-of-life care, BMC Nursing

The article, led by Issa Beatriz Palomata and Joshua D. Guzman of San Francisco State University, with Britney Momanyi of Cornell University and senior author Kala M. Mehta of the University of California, San Francisco, does not set out to condemn medical missions as a model of care. Instead, the authors aim to strengthen the experience for patients, host communities, and the students who participate. Their central insight is deceptively simple: medical missions function as sites of early professional socialization. Long before medical school teaches a future physician about scope of practice, informed consent, or health system stewardship, a volunteer trip abroad is already absorbing implicit norms about what is professionally acceptable, through direct experience rather than instruction.

This matters because the risks of poorly designed missions are well documented in the global health literature. Temporary relief may be delivered while local health systems remain under-resourced or increasingly reliant on external aid. Short-term interventions can disrupt existing care pathways rather than strengthening them. Patients screened for hypertension during a visit may have no clear mechanism for reassessment once the team departs. Supplies run out, patients are turned away, and local providers may be bypassed rather than supported. These outcomes, the authors stress, typically reflect structural limitations in how missions are designed and evaluated, not malicious intent on the part of volunteers.

What makes the new contribution distinctive is its focus on the premedical and trainee stage, a point in the pipeline that prior literature has largely overlooked. Established ethical frameworks for global health engagement already exist, including widely cited guidelines for responsible short-term experiences and impact-driven principles developed by teams in academic medicine and global health. Far less attention has been given to premedical students specifically, even though they occupy a distinctive position between observation and participation, supplying needed person power while absorbing professional norms through firsthand experience. The authors argue that this stage is a critical point for ethical intervention before formal medical training begins.

The article draws on the firsthand experience of Palomata during a 2024 medical mission in Bayambang, Pangasinan Province, in the Philippines. There, gymnasiums were converted into temporary clinics where hundreds of patients were screened for hypertension and diabetes or treated for conditions left unaddressed for months or years. Palomata assisted with medication distribution, translation, and minor procedures. In one interaction that now anchors the article’s argument, she translated a patient report for a woman with markedly elevated, previously unchecked blood pressure, enabling the clinician to initiate treatment. That screening may have been the patient’s only cardiovascular assessment, with no clear mechanism for reassessment once the visiting team left. The episode illustrates the core tension between resource burden and continuity of care that the proposed tool is designed to surface.

That tool is a structured reflection instrument with prompts organized around three phases: before departure, during service, and after return. The design reflects a technical premise about how ethical reasoning develops. If missions are early sites of professional socialization, ethical reflection must be structured rather than left to chance: introduced before departure, applied during service, and revisited upon return. Used before a trip, the prompts might lead a student to weigh whether a role like translation truly reduces burden on local staff. Used during the mission, they push students to remain within the scope-of-practice boundaries that would apply at home, a boundary that the Philippine experience showed can blur informally when tasks restricted for students in the United States occasionally become permissible abroad. Used after return, the tool invites students to ask whether the anticipated benefits of their participation held up in practice.

The authors are careful about what the tool is and is not. It is not intended to replace existing curricula. Some institutions already provide structured pre-departure orientation or post-mission debriefing, and the instrument is meant to complement such efforts while offering a starting point for programs without a comparable framework. It is explicitly framed as a prototype for future empirical evaluation rather than a validated intervention. Supervising clinicians retain formal responsibility for patient care; the tool instead shapes how premedical students come to understand equity, accountability, and professional boundaries as they enter the field. Program directors can draw on aggregate, de-identified themes from student reflections as one input into program review, without repurposing the tool itself as an institutional compliance instrument.

Accountability, the authors argue, must operate at both the student and the institutional level, and the article enumerates a demanding set of obligations for each. Students are responsible for using the reflection tool honestly, remaining within scope-of-practice boundaries, prioritizing meaningful contribution over resume-building or personal educational gain, and reflecting critically before, during, and after participation. Universities and mission organizations carry a broader burden: conducting community needs assessments in partnership with local health authorities, involving local healthcare professionals and community representatives in planning and oversight, providing mandatory pre-departure training in cultural humility, local health systems, and language accessibility, establishing feedback channels with host communities and providers, and maintaining post-mission follow-up mechanisms.

Underlying all of this is a model of engagement the authors describe as listen-first, in which visiting clinicians work alongside local providers through co-management and mentorship rather than bypassing local health workers. Longstanding institutional partnerships, built on reciprocity and sustained dialogue rather than one-off service delivery, are what allow missions to avoid becoming extractive. Shared decision-making with local providers and structured opportunities for host communities to shape future visits are essential. Students, the authors suggest, are a pivotal part of this process precisely because they have not yet been shaped by formal training and can listen with compassion and understanding. Framed this way, a mission’s goal is to strengthen the local health system, not merely to deliver services to it.

The article closes with a reflection that gives the technical argument its emotional weight. Looking back on the registration line stretching beyond the gymnasium entrance in Pangasinan, and on patients turned away once supplies ran out, Palomata and colleagues describe the scene not only as one of unmet need but as an early lesson in what it means to take responsibility for the limits of the care medical professionals provide. Improving medical missions, they conclude, requires more than institutional redesign; it requires recognizing that professional identity formation begins early, before formal medical training. Student reflection and institutional accountability must work together if that lesson is to translate into lasting change, and the authors encourage students to engage with the tool before departure and revisit it after return, creating structured space for critical reflection while institutions retain responsibility for the structural conditions of the mission itself.

Subject of Research: A structured three-phase reflection tool aims to embed ethical engagement in medical missions at the premedical and trainee stage, before formal medical training begins.

Article Title: Improving medical missions: A student and trainee tool for ethical engagement

Article References: Palomata, I. B., Guzman, J. D., Momanyi, B., & Mehta, K. M. (2026). Improving medical missions: A student and trainee tool for ethical engagement. PLOS Global Public Health, 6(10), e0007415. https://doi.org/10.1371/journal.pgph.0007415

Image Credits: AI Generated

DOI: 10.1371/journal.pgph.0007415

Keywords: medical missions, global health, premedical students, medical ethics, PLOS Global Public Health, professional socialization, health equity, volunteerism, Improving, medical, missions, student

VCA differs fundamentally from solid organ transplantation. Instead of replacing a heart or kidney, surgeons transfer composite tissues such as skin, muscle, bone, vessels, and nerves to restore structures like hands, faces, abdominal walls, uteri, and genitourinary organs. Contemporary procedures aim not only to rebuild anatomy and physical function but also to improve what clinicians call embodiment, identity, dignity, autonomy, and social participation in patients who have suffered devastating tissue loss. That ambition, however, comes with a distinctive ethical tension. Unlike a heart transplant, most VCA procedures are life enhancing rather than life saving, which forces clinicians to weigh functional benefit against the lifelong risks of immunosuppressive therapy, including infection, malignancy, and metabolic disease.

The special issue opens with a historical lens. A bibliometric analysis by Njessi and colleagues examined the one hundred most cited publications in the field and traced how the scientific literature has been shaped by hand and face transplantation, immunological innovation, rehabilitation science, and ethical discourse. The analysis underscores just how interdisciplinary contemporary VCA research has become, with no single specialty able to claim ownership of the field’s progress. It also provides a useful benchmark for measuring which areas, such as tolerance induction and digital monitoring, are now generating momentum and which remain underexplored.

Technological innovation features prominently throughout the collection. A systematic review by Chakradhar and colleagues synthesizes emerging technologies in immunomodulation, targeted drug delivery, tolerance induction, machine perfusion, biomarkers, and digital innovation. Among the most promising approaches are localized tacrolimus delivery systems that concentrate immunosuppressive drug action at the graft itself, hydrogel based immunosuppressive platforms that release medication gradually, mesenchymal stem cell therapies that may recalibrate the immune response, and mixed chimerism protocols designed to persuade the recipient’s immune system to accept donor tissue as self. The overarching goal is to reduce the burden of lifelong systemic immunosuppression while improving graft survival and enabling genuinely individualized care, a combination that would fundamentally alter the risk-benefit calculus for prospective recipients.

One of the most striking translational contributions comes from Duru and colleagues, who demonstrated successful twenty four hour ex vivo perfusion of vascularized composite allografts in a large animal limb model. Prolonged extracorporeal preservation of this kind could transform donor logistics across the field. Currently, the viability window for composite tissue grafts is short, which constrains how far donor organs can travel, how thoroughly donor and recipient can be matched, and how much time surgical teams have to plan complex multi-team operations. If extended preservation proves safe in humans, it could mitigate ischemia reperfusion injury, broaden geographic allocation, and ultimately widen access to VCA for patients far from the handful of centers currently performing these procedures.

The issue also reaches into specialized domains of transplantation medicine. D’Elia and colleagues reviewed immunosuppressive management in uterine VCA and pregnancy, a setting with unique challenges. Uterine grafts are temporary by design, intended to be removed after successful childbirth, and the immunological relationship between mother and fetus adds a second layer of complexity. Pregnancy itself alters the pharmacokinetics of immunosuppressive drugs, meaning that blood levels can shift unpredictably across trimesters. The authors emphasize the need for individualized therapeutic monitoring, pregnancy compatible immunosuppressive agents, and future development of noninvasive rejection monitoring and tolerance inducing approaches that could protect both mother and developing child.

Yet the collection’s central message is that technology alone cannot define success. Kumnig’s own mini review argues for a biopsychosocial technological framework that integrates biomedical advances with psychosocial care, ethical reflection, and patient centered research. Meaningful outcome assessment in VCA, the review contends, must extend well beyond graft survival and technical outcomes to incorporate quality of life, psychosocial resilience, rehabilitation adherence, informed decision making, embodiment, and social reintegration. This reframing matters because a technically perfect hand graft that the recipient neglects in rehabilitation, or a facial graft that fails to restore social confidence, represents a very different kind of outcome than the surgical record alone would suggest.

Psychosocial evaluation receives detailed attention. Antas and Nyberg, drawing on the Finnish experience with VCA, describe psychosocial suitability as a dynamic and multidimensional construct that extends far beyond the simple absence of psychiatric illness. Their work highlights psychosocial functioning, cognitive capacity, social context, and mentalization capacity, which is the ability to understand one’s own and others’ mental states, as particularly important dimensions for preoperative evaluation and long term follow up. Because VCA recipients must adhere to complex medication regimens, attend frequent monitoring appointments, and engage in years of rehabilitation, the assessment of suitability is not a one-time gatekeeping exercise but a continuous process that evolves with the patient’s circumstances.

Ethical and developmental questions come into sharpest focus in a contribution by McKenna and colleagues on facial transplantation in emerging adulthood. Individuals between eighteen and twenty five years of age occupy a unique position in the VCA landscape. On one hand, they may be among the patients who stand to benefit most, since restoring a face at a life stage dominated by identity formation and social integration could yield profound improvements in personal development and participation. On the other hand, ongoing cognitive development in this age group may complicate informed consent, treatment adherence, and long term decision making. The authors advocate for developmentally tailored psychosocial support strategies specifically designed for this vulnerable yet potentially highly benefiting population, a recommendation that could influence patient selection protocols at VCA centers worldwide.

Taken together, the contributions offer a roadmap for the coming decades of VCA research and clinical implementation. The editors and authors converge on several structural priorities: harmonized international registries to pool outcomes across centers, standardized psychosocial outcome measures so that results from different programs can be compared, long term follow up protocols that track recipients for decades rather than years, and ethically grounded frameworks for patient selection and informed consent. Advances in immunomodulation, machine perfusion, digital technologies, and regenerative approaches continue to expand what is surgically possible, but the field’s own analysis suggests that sustainable progress depends equally on patient centered care, equitable access, and the capacity to support the complex psychological, social, and ethical realities that recipients navigate throughout their lifelong transplantation journey. As VCA moves from experimental achievement toward established clinical practice, the measure of its success will increasingly be written in the quality of recipients’ lives rather than in the record books of surgical firsts.

Subject of Research: Vascularized composite allotransplantation research and interdisciplinary clinical evolution

Article Title: Editorial: How current and future approaches and research results contribute to evolve the field of vascularized composite allotransplantation

Article References: Kumnig, M. (2026). Editorial: How current and future approaches and research results contribute to evolve the field of vascularized composite allotransplantation. Frontiers in Transplantation, 5, Article 1993324. https://doi.org/10.3389/frtra.2026.1993324

Image Credits: AI Generated

DOI: 10.3389/frtra.2026.1993324

Keywords: vascularized composite allotransplantation, hand transplantation, face transplantation, immunosuppression, machine perfusion, psychosocial assessment, tissue grafts, medical ethics, rehabilitation medicine, transplantation immunology, patient-centered medicine, Editorial